Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: A double-blind crossover study in individuals with type 2 diabetes

Diabetes Care

Volumn 30, Issue 5, 2007, Pages 1044-1048

  McNally, Paul G ^a   Dean, John D ^b   Morris, Andrew D ^c   Wilkinson, Peter D ^d   Compion, Gerhard ^e   Heller, Simon R ^f  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b BOLTON NHS FOUNDATION TRUST   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d Wilkinson Associates   (United Kingdom)

^e Novo Nordisk Ltd   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; INSULIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SELF REPORT;

AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MONITORING, AMBULATORY; SELF CARE;

EID: 34247552255     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1328     Document Type: Article

References (21)

1. Leese PG, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD, the DARTS/MEMO Collaboration: Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 26:1176-1180, 2003
2. Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, Windfeld K, Lindholm A: Hypoglycemia with insulin aspart: a double-blind, randomized, crossover trial in subjects with type 1 diabetes. Diabet Med 21:769-775, 2004
3. Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B: Reproducibility and reliability of hypoglycemic episodes recorded with Continuous Glucose Monitoring System (CGMS) in daily life. Diabet Med 22:858-862, 2005
4. Monsod TP, Flanagan DE, Rife F, Saenz R, Caprio S, Sherwin RS, Tamborlane WV: Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 25:889-893, 2002
5. Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS: A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as assessed using the continuous glucose MiniMed monitor. Diabetes Care 26:548-549, 2003
6. Aussedat B, Dupire-Angel M, Gifford R, Klein JC, Wilson GS, Reach G: Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab 278:E716-E728, 2000
7. Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ: Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care 26:2405-2409, 2003
8. Chico A, Vidal-Rios P, Subirà M, Novials A: The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 26:1153-1157, 2003
9. Kapitza C, Lodwig V, Obermaier K, Wientjes KJ, Hoogenberg K, Jungheim K, Heineman L; Glucose Monitoring Study Group: Continuous glucose monitoring: reliable measurements for up to 4 days with the SCGM1 system. Diabetes Technol Ther 5:609-614, 2003
10. Sachedina N, Pickup JC: Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycemic control in type 1 diabetic subjects. Diabet Med 20:1012-1015, 2003
11. Conrad SC, Mastrototaro JJ, Gitelman SE: The use of a continuous glucose monitoring system in hypoglycemic disorders. J Pediatr Endocrinol Metab 17:281-288, 2004
12. Goldberg PA, Siegel MD, Russel RR, Sherwin RS, Halickman JI, Cooper DA, Dziura JD, Inzucchi SE: Experience with continuous blood glucose monitoring system in a medical intensive care unit. Diabetes Technol Ther 6:339-347, 2004
13. Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, Phillip M: Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion. Arch Pediatr Adolesc Med 158:677-684, 2004
14. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
15. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653-1659, 2001
16. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J: Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 42:1233-1237, 1993
17. Home PD, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 55:199-203, 1999
18. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR: Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 22:1501-1506, 1999
19. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, the INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265, 2005
20. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M: Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus oncedaily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 114:527-532, 2006
21. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R: Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 8:58-66, 2006